Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
26 Results for "
MAPKAPK2
" in MedChemExpress (MCE) Product Catalog:
Products (26)
26 Results for "MAPKAPK2" in MCE Product Catalog:
6
6 Publications Verification
Target:
Research Areas:
MK2-IN-1 hydrochloride (compound 1) is a potent and selecitve MAPKAPK2 (MK2) inhibitor with an IC50 of 0.11 uM for MK2 and an EC50 of 0.35 uM for pHSP27. MK2-IN-1 hydrochloride impaires the phosphorylation level of serine residues in the Tfcp2l1 protein [2].
6
6 Publications Verification
Target:
Research Areas:
MK2-IN-1 (compound 1) is a potent and selecitve MAPKAPK2 (MK2) inhibitor with an IC50 of 0.11 uM for MK2 and an EC50 of 0.35 uM for pHSP27. MK2-IN-1 impaires the phosphorylation level of serine residues in the Tfcp2l1 protein [2].
5
5 Cited Publications
Target:
Research Areas:
MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC50 of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC50s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC50s>200 μM). MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo .
5
5 Cited Publications
Target:
Research Areas:
MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 8.5 nM.MK2-IN-3 hydrate is exceptional selectivity against MK-3 (IC50=0.21 μM), MK-5 (IC50=0.081 μM), ERK2 (IC50=3.44 μM), MNK1(IC50=5.7 μM) as well as CDK2, JNK2, IKK2, MSK1, and MSK2 .
2
2 Cited Publications
Target:
Research Areas:
PF-3644022 is a potent, selective, orally active and ATP-competitive MAPKAPK2 (MK2) inhibitor with an IC50 of 5.2 nM and a Ki of 3 nM. PF-3644022 also inhibits MK3 and p38 regulated/activated kinase (PRAK) with IC50s of 53 nM and 5.0 nM, respectively. PF-3644022 potently inhibits TNFα production and has anti-inflammatory effect .
Target:
PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK)
Research Areas:
DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity .
Cat. No.: HY-16129
CAS No.: 565434-85-7
Research Areas:
Target:
PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) LIM Kinase (LIMK) ULK
Research Areas:
DB0614 is a PROTAC based on Cereblon ligand, which is a selective and potent targeted protein degrader of NEK9 inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity [2].(Blue: Thalidomide-4-OH (HY-103596), Black: linker, Pink: FLT3-IN-17 (HY-148070))
Cat. No.: HY-RS08131
Target:
Research Areas:
MAPKAPK2 Human Pre-designed siRNA Set A contains three designed siRNAs for MAPKAPK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS08132
Target:
Research Areas:
Mapkapk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mapkapk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-175809
Target:
Research Areas:
SRT6 is a CD44 inhibitor. SRT6 exerts antiproliferative activity in CD44 + breast cancer and lung cancer cells. SRT6 inhibits CD44-associated SRC kinase, as well as EGFR, ERBB2, ERBB4, MAP3K10 and MAPKAPK2. SRT6 can be used for the research of breast cancer and lung cancer .
Cat. No.: HY-RS08133
Target:
Research Areas:
Mapkapk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mapkapk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-16129A
Research Areas:
Cat. No.: HY-P10367
CAS No.: 518069-98-2
Research Areas:
Cat. No.: HY-147283
CAS No.: 1105658-32-9
Target:
Research Areas:
MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor with an IC50 value of 45 nM. MK2-IN-4 can be used in the research of cancer, inflammation, immunology .
Cat. No.: HY-P701804
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: MAPKAPK2; MAP kinase-activated protein kinase 2; MAPK-activated protein kinase 2; MAPKAP kinase 2; MAPKAP-K2; MAPKAPK-2; MK-2; MK2
Cat. No.: HY-P701805
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: MAPKAPK2; MAP kinase-activated protein kinase 2; MAPK-activated protein kinase 2; MAPKAP kinase 2; MAPKAP-K2; MAPKAPK-2; MK-2; MK2
Cat. No.: HY-P705848
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: MAPKAPK2; MAP kinase-activated protein kinase 2; MAPK-activated protein kinase 2; MAPKAP kinase 2; MAPKAP-K2; MAPKAPK-2; MK-2; MK2
Cat. No.: HY-P702662
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: MAPKAPK2; mitogen-activated protein kinase-activated protein kinase 2; MAP kinase-activated protein kinase 2; MAPKAP kinase 2; MAPK-activated protein kinase 2; MK2; MK-2; MAPKAP-K2
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
